Datapoint: Pfizer Scores Multiple Myeloma Nod for Elrexfio

The FDA last week approved Pfizer’s Elrexfio for the treatment of relapsed or refractory multiple myeloma in adult patients that have received at least four prior lines of treatment, “including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.” The drug will face off against Johnson & Johnson’s Tecvayli, another BCMA-directed bispecific antibody. Both drugs are administered as subcutaneous injections, though Elrexfio may edge out Tecvayli on convenience. The J&J therapy requires weekly administration, while Elrexfio is given biweekly. For the treatment of multiple myeloma, Tecvayli currently holds covered or better status for 85% of all insured lives under the medical benefit. About 21% of lives have preferred access to Tecvayli.

SOURCE: MMIT Analytics, as of 8/21/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 29

Datapoint: FDA Approves Latest Humira Biosimilar

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 28

Datapoint: Xolair Scores FDA Nod for Food Allergies

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 27

Datapoint: Aetna Sees Strong MA Growth

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today